logo
Plus   Neg
Share
Email

MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

MorphoSys AG (MOR,MPSYY.PK) and Incyte Corp. (INCY) have agreed on a collaboration and license agreement to further develop and commercialize MorphoSys' anti-CD19 antibody tafasitamab (MOR208) globally. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S. Incyte has exclusive commercialization rights outside of the U.S.

Tafasitamab is an Fc-engineered antibody currently in clinical development for the treatment of B cell malignancies. MorphoSys recently submitted a Biologics License Application for tafasitamab, in combination with lenalidomide, to the FDA for the treatment of relapsed/refractory diffuse large B cell lymphoma.

MorphoSys will receive an upfront payment of $750 million. Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys. Under the terms of the agreement, MorphoSys will be also eligible to receive milestone payments amounting to up to $1.1 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT